NADClinic introduces South Africa’s first NAD+ smart pen, expanding access to personalised longevity medicine.
As demand for evidence-based longevity medicine continues to accelerate, NADClinic South Africa has announced the launch of the NAD+ SQx Smart Pen; a next-generation self-administration device designed to make pharmaceutical-grade NAD+ therapy more convenient, flexible and accessible than ever before.
The launch marks another milestone in the evolution of longevity medicine, allowing eligible patients to continue their NAD+ protocols from home, while travelling or around busy schedules without compromising on clinical quality or precision.
“The future of healthcare isn’t simply about living longer; it’s about making preventative, evidence-based medicine easier to integrate into everyday life,” says Dr Siddharth Govender, Medical Director at NADClinic South Africa. “The NAD+ SQx Smart Pen represents exactly that. It combines clinical innovation with convenience while maintaining the pharmaceutical standards our patients expect.”
Supporting cellular health from the inside out
NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme found in every cell of the body and is essential for energy production, DNA repair and healthy cellular function. Levels naturally decline with age and may also be affected by chronic stress, illness and lifestyle factors, contributing to reduced energy, slower recovery and other signs associated with ageing.
“By supporting cellular health, NAD+ therapies may form part of a medically supervised longevity programme aimed at promoting healthy ageing, improving vitality and optimising overall wellbeing,” Dr Govender explains. “Depending on the individual’s clinical needs, potential benefits may include support for sustained energy, cognitive performance, metabolic health, recovery, healthy ageing, sleep quality, skin health and physical performance.”
Precision meets convenience
Unlike traditional injectable delivery methods, the NAD+ SQx Smart Pen has been engineered for simple, precise self-administration. Patients can adjust doses according to their prescribed protocol while benefiting from pharmaceutical-grade NAD+ manufactured to internationally recognised quality standards. The pen incorporates anti-counterfeit safeguards and is produced in certified manufacturing facilities with comprehensive quality testing to ensure consistency and product integrity.
“The Smart Pen isn’t designed to replace clinical care,” explains Dr Govender. “It is intended to extend it; patients still undergo medical assessment and receive personalised treatment plans, but the difference is that ongoing therapy can now fit far more seamlessly into modern lifestyles.”
Part of a comprehensive longevity ecosystem
The Smart Pen joins NADClinic South Africa’s growing portfolio of evidence-based longevity therapies, which includes:
- Intravenous NAD+ infusions
- NADSQ subcutaneous NAD+ injections
- Personalised longevity consultations
- Comprehensive diagnostics and biomarker testing
- Medical weight optimisation programmes
- Precision supplementation and lifestyle optimisation
“Rather than focusing on a single intervention, NADClinic’s approach combines advanced diagnostics, medical expertise and evidence-based therapies to develop personalised programmes that address healthspan, which is the number of years spent living in good health,” he adds. “Longevity medicine is becoming increasingly personalised, and there is no one-size-fits-all solution; our role is therefore to understand each patient’s biology and develop a programme that supports long-term health, resilience and performance.”
Availability
The NAD+ SQx Smart Pen is now available through NADClinic South Africa following consultation with a qualified healthcare professional to determine clinical suitability.
Patients can learn more about the therapy, available treatment programmes and pricing by visiting the NADClinic website: www.nadclinic.co.za.
